ANRS, Emerging Infectious Diseases
247
20
29
122
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
6.9%
17 terminated/withdrawn out of 247 trials
87.8%
+1.2% vs industry average
19%
46 trials in Phase 3/4
7%
9 of 122 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (247)
DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection
Role: lead
ARN-75039 Lassa Fever Treatment in West Africa
Role: collaborator
Education of Medical Staff to Post Acute Covid susTained sYmptoms
Role: collaborator
Efficacy of Tenofovir Disoproxil on Mother-to-child Transmission of HBV in Tokombéré, Cameroon in Pregnant Women
Role: lead
Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis
Role: lead
Intestinal Tissue-Resident Memory T Cells and HIV-1 Persistence During Antiretroviral Therapy
Role: lead
Liver Transplantation in Patients With Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Coinfection
Role: lead
Salvage Therapy With Amprenavir, Lopinavir and Ritonavir in HIV-infected Patients in Virological Failure.
Role: lead
Pilot Study on Once Daily FTC, ddI, Efavirenz Combination in Antiretroviral Naive HIV Infected Adults
Role: lead
Once Daily Antiretroviral Therapy in HIV Infected Adults Treated With HAART
Role: lead
Antibody Responses to Pneumococcal Vaccines Among HIV-infected Adults.
Role: lead
Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir
Role: lead
Prospective Cohort of People Starting Treatment for Tuberculosis Disease in France (FrenchTB)
Role: lead
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load
Role: lead
A Prophylactic HIV Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DREP Alone and in Combination With a Clade C ENV Protein in Healthy HIV-uninfected Adults
Role: lead
Reducing Antiretroviral Treatments
Role: lead
Study Comparing the Tolerability and Viral Reduction of the Combination of IFN a-2b XL + Ribavirin Versus Peg IFN a-2b + Ribavirin in Patients With Chronic Hepatitis C, Genotype 1 or 4
Role: lead
Efficacy of Ultraviolet Germicidal Irradiation Devices to Reduce Respiratory Infections in Nursing Homes: Cluster Randomized Crossover Trial
Role: collaborator
An Experimental Medicine Multicenter Trial to Evaluate the Safety and Immunogenicity of Experimental Versus Authorized SARS-CoV-2 Vaccine Candidates as a Booster Dose in Healthy Participants Previously Vaccinated With Authorized mRNA SARS-CoV-2 Vaccines.
Role: lead
Assessment of the Efficacy and Safety of Tecovirimat in Patients With Monkeypox Virus Disease
Role: lead